Sino Biopharmaceutical (HKG:1177) presented the latest results of a Benmelstobart injection study to treat advanced squamous non-small cell lung cancer at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, a Friday Hong Kong bourse filing said.
The phase III clinical trial studies the use of the drug in combination with chemotherapy, followed by sequential combination with Anlotinib Hydrochloride capsules, versus the Tislelizumab injection in combination with chemotherapy.
The trial shows that the drug in combination with the other therapies significantly prolonged median progression-free survival compared with Tislelizumab, reducing the risk of disease progression or death by 36% in the trial group.
The overall safety of the trial group was also good.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.